title: [KIT and KIT: from biology to clinical use].
abstract: Scientific knowledge on gastrointestinal stromal tumors (GIST) has highly progressed over the last 10 years. The molecular bases of oncogenic transformation, KIT activating mutations, were identified in 1998 by Hirota et al. The product of KIT proto-oncogene, KIT protein, is a transmembrane receptor with tyrosine kinase activity. Tyrosine kinase inhibitors targeting these mutated activated kinases, namely imatinib and more recently sunitinib, nilotinib, masitinib or sorafenib, have deeply modified GIST prognosis. Molecular biology in GIST is now becoming a routine tool for treatment selection. In patients with advanced GIST, imatinib should be given until progression, and then, other tyrosine kinase inhibitors targeting KIT should be used. In the adjuvant setting, the optimal duration of imatinib treatment remains unknown.
authors.affiliation: CHU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon Cedex, France. elsa.curtit7@wanadoo.fr
authors.forename: Elsa
authors.initials: E
authors.lastname: Curtit
authors.forename: Laura
authors.initials: L
authors.lastname: Mansi
authors.forename: Erika
authors.initials: E
authors.lastname: Viel
authors.forename: Erion
authors.initials: E
authors.lastname: Dobi
authors.forename: Loïc
authors.initials: L
authors.lastname: Chaigneau
authors.forename: Thierry
authors.initials: T
authors.lastname: Nguyen
authors.forename: Xavier
authors.initials: X
authors.lastname: Pivot
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Elsa
authors.initials: E
authors.lastname: Kalbacher
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001557:Benzenesulfonates / Q000627:therapeutic use; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines / Q000627:therapeutic use; D010880:Piperidines; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000090063:Proto-Oncogene Mas; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001557:Benzenesulfonates; D007211:Indoles; C000715470:MAS1 protein, human; D010671:Phenylurea Compounds; D010879:Piperazines; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D000090063:Proto-Oncogene Mas; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D013844:Thiazoles; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D019009:Proto-Oncogene Proteins c-kit; C498826:nilotinib; C526575:masitinib; D000077210:Sunitinib